• Users Online: 424
  • Print this page
  • Email this page
Year : 2019  |  Volume : 2  |  Issue : 1  |  Page : 19-21

Resurgence of role of radiotherapy in neoadjuvant treatment of pancreatic cancer

Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Correspondence Address:
Dr. Kaustav Talapatra
Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Four Bungalows, Andheri (W), Mumbai 400 053
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCO.JCO_23_18

Rights and Permissions

Borderline resectable pancreatic cancer (BRPC) is a clinically distinguished malignancy. With limited role of aggressive surgical intervention, neoadjuvant treatment is warranted. Various studies and their meta-analysis addressing this issue have shown limited benefit. However, recently two prospective multiple randomized trials have evaluated benefit of neoadjuvant chemoradiotherapy in BRPC with a positive clinical response. This article gives a brief insight into these studies and discusses future prospects for role of radiation in neoadjuvant setting in pancreatic cancer.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded406    
    Comments [Add]    

Recommend this journal